Comparative Pharmacology
Head-to-head clinical analysis: DISOMER versus KALLIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOMER versus KALLIGA.
DISOMER vs KALLIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective dopamine D2 receptor antagonist; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
KALLIGA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and easily excreted metabolite, thereby reducing serum uric acid levels.
Adults: 1 mg orally once daily.
0.5 mg orally once daily, titrated to 1 mg once daily after 2-4 weeks if tolerated.
None Documented
None Documented
12–15 hours in adults with normal renal function; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; <5% unchanged in feces.
Renal excretion: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Antihistamine
Antihistamine